BioMarin's BRINEURA Receives FDA Approval for All Ages with CLN2 Disease
FDA expands BioMarin's BRINEURA approval to treat all ages with CLN2 disease, including children under 3.
BioMarin Pharmaceutical has announced that the U.S. Food and
Drug Administration (FDA) has expanded the approval of its drug, BRINEURA
(cerliponase alfa), to treat children of all ages with CLN2 disease, also known
as Batten disease. Previously, the drug was only approved for symptomatic
children aged 3 and above.
This expanded approval is based on a clinical trial showing
that BRINEURA can slow the progression of the disease, even in children under 3
years old who may not yet show symptoms. The drug is administered directly into
the cerebrospinal fluid and works by replacing a missing enzyme.
CLN2 disease is a rare genetic disorder that causes
progressive damage to the brain and nervous system. It typically begins with
seizures and language delays and eventually leads to blindness, loss of motor
function, and death. There is currently no cure for the disease.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®
Discussion